Non-genetic engineering of cells for drug delivery and cell-based therapy
Abstract
Cell-based therapy is a promising modality to address many unmet medical needs. In addition to genetic engineering, material-based, biochemical, and physical science-based approaches have emerged as novel approaches to modify cells. Non-genetic engineering of cells has been applied in delivering therapeutics to tissues, homing of cells to the bone marrow or inflammatory tissues, cancer imaging, immunotherapy, and remotely controlling cellular functions. This new strategy has unique advantages in disease therapy and is complementary to existing gene-based cell engineering approaches. A better understanding of cellular systems and different engineering methods will allow us to better exploit engineered cells in biomedicine. Here, we review non-genetic cell engineering techniques and applications of engineered cells, discuss the pros and cons of different methods, and provide our perspectives on future research directions.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The ureteric epithelium develops from early migrating presomitic mesoderm cells.
“it is known that the ureteric epithelium develops from early migrating presomitic mesoderm cells.”
From Organoids (2022) · cites this paper as [84]
The citation lists haven’t been fetched yet
References 248 · Cited by 225
- Authors
- Wang, Q., Cheng, H., Peng, H., Zhou, H., Li, P. Y., & Langer, R.
- Affiliations
- Harvard University (US)
- Drexel University (US)
- Iowa State University (US)
- Corresponding author
- Cheng, Hao
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 91
- Pages
- 125-140
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2026185209
- Cited by
- 225
- References
- 248
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 15 · 2023: 13 · 2022: 24 · 2021: 23 · 2020: 31 · 2019: 19 · 2018: 37 · 2017: 29 · 2016: 12 · 2015: 3
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Drug Delivery Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Jorge Heller Postdoctoral Fellowship
- Clinical and Translational Research Institute (CTRI) and Drexel University
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
- Keywords
- engineered cells, cell therapy, drug delivery, cell homing, bone marrow homing, tumor imaging, immunotherapy, cell modification
- MeSH terms
- Animals, Cell Membrane, Humans, Immunotherapy, Drug Delivery Systems, Cell Engineering, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review